Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2111348 Target Snapshot

Soluble guanylate cyclase · PROTEIN COMPLEX GROUP · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
620Compounds
32Assays
0Approved Drugs
544.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Soluble guanylate cyclase shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q02153. Start with cardiovascular disease, then reuse UniProt Q02153 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cardiovascular disease, then reuse UniProt Q02153 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
cardiovascular disease

Soluble guanylate cyclase shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include ISOSORBIDE DINITRATE, ISOSORBIDE MONONITRATE, NITROGLYCERIN, PENTAERYTHRITOL TETRANITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Soluble guanylate cyclase as ChEMBL target CHEMBL2111348, mapped to UniProt Q02153. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Soluble guanylate cyclase
PROTEIN COMPLEX GROUP · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2111348
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q02153
Guanylate cyclase soluble subunit beta-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Soluble guanylate cyclase is the right protein anchor across sources, using UniProt Q02153 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cardiovascular disease is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSoluble guanylate cyclase
Target TypePROTEIN COMPLEX GROUP
OrganismHomo sapiens
UniProtQ02153
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGuanylate cyclase soluble subunit beta-1
UniProt AccessionQ02153
Component TypeProtein
Sequence Length619 aa

Guanylate cyclase soluble subunit beta-1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Soluble guanylate cyclase, mapped to UniProt Q02153. ChEMBL maps the protein component as Guanylate cyclase soluble subunit beta-1. Sequence length is 619 aa.

Mapped IDQ02153
Review nameSoluble guanylate cyclase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Soluble guanylate cyclase shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cardiovascular disease
6 linked drugs · 6 direct · 6 efficacy
Linked drugISOSORBIDE DINITRATE
Linked drugISOSORBIDE MONONITRATE
Linked drugNITROGLYCERIN
Linked drugPENTAERYTHRITOL TETRANITRATE
Approved-linked Approved
heart failure
6 linked drugs · 6 direct · 6 efficacy
Linked drugCINACIGUAT
Linked drugISOSORBIDE DINITRATE
Linked drugISOSORBIDE MONONITRATE
Linked drugNITROGLYCERIN
Approved-linked Approved
congestive heart failure
5 linked drugs · 5 direct · 5 efficacy
Linked drugCINACIGUAT
Linked drugISOSORBIDE DINITRATE
Linked drugNITRIC OXIDE
Linked drugNITROGLYCERIN
Approved-linked Approved
hypertension
4 linked drugs · 4 direct · 4 efficacy
Linked drugISOSORBIDE MONONITRATE
Linked drugNITROGLYCERIN
Linked drugRIOCIGUAT
Linked drugSODIUM NITROPRUSSIDE
Approved-linked Approved
angina pectoris
3 linked drugs · 3 direct · 3 efficacy
Linked drugISOSORBIDE DINITRATE
Linked drugISOSORBIDE MONONITRATE
Linked drugNITROGLYCERIN
Approved-linked Approved
coronary artery disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugISOSORBIDE DINITRATE
Linked drugISOSORBIDE MONONITRATE
Linked drugNITROGLYCERIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include ISOSORBIDE DINITRATE, ISOSORBIDE MONONITRATE, NITROGLYCERIN, PENTAERYTHRITOL TETRANITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecardiovascular disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
Assay Mix

Activity Type Distribution

IC509.0
EC50533.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3892047 9.0 EC50 1.0 Preclinical
CHEMBL3895428 9.0 EC50 1.0 Preclinical
CHEMBL3904056 9.0 EC50 1.0 Preclinical
CHEMBL3914172 9.0 EC50 1.0 Preclinical
CHEMBL3925984 9.0 EC50 1.0 Preclinical
CHEMBL3940979 9.0 EC50 1.0 Preclinical
CHEMBL3894281 8.7 EC50 2.0 Preclinical
CHEMBL3896300 8.7 EC50 2.0 Preclinical
CHEMBL3901016 8.7 EC50 2.0 Preclinical
CHEMBL3905803 8.7 EC50 2.0 Preclinical
Distribution

pChEMBL Value Distribution

60
5.0
40
5.5
33
6.0
45
6.5
59
7.0
97
7.5
92
8.0
45
8.5
6
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

32
Total Assays
507
Tested Compounds
2
Assay Types
Binding — 27 assays, 507 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 18 64 5.9
cell-based format 8 337 7.7
assay format 1 106 5.2
Functional — 5 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 1 4.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine